论文部分内容阅读
【目的】探讨孟鲁司特对小儿变应性紫癜（HSP）患者治疗前后白细胞介素‐6（IL‐6）、白细胞介素‐12（IL‐12）的影响及其临床疗效。【方法】100例 HSP患儿随机分为试验组和对照组，每组50例，对照组采用常规治疗方案，试验组在常规治疗的基础上加上孟鲁司特治疗，两组的治疗周期均为3周。比较两组治疗前后IL‐6、IL‐12的变化情况，同时观察并比较两组的临床疗效。【结果】治疗后，试验组和对照组患儿血清细胞因子IL‐6、IL‐12水平均较治疗前明显下降，且差异均有显著性（ P ＜0．01）；试验组IL‐6、IL‐12水平明显低于对照组，且差异均有显著性（ P ＜0．05）；试验组治疗总有效率（96．0％）明显高于对照组（76．0％），皮疹消退时间（5．8±1．2d）、腹痛缓解时间（11．5±1．6d）和关节肿痛消退时间（12．8±4．2d）均明显优于照组，且差异均有显著性（ P ＜0．05）。【结论】在常规治疗基础上辅以孟鲁司特治疗小儿 HSP能明显降低IL‐6、IL‐12水平，患儿总有效率及临床症状改善时间方面优于常规治疗。“,”[Objective] To explore the effects of montelukast on interleukin‐6 (IL‐6) and interleukin‐12 (IL‐12) in patients with Henoch‐Schonlein purpura (HSP) and its clinical efficacy .[Methods] A total of 100 HSP children were randomly divided into experimental and control groups (n=50 each) .The control group received conventional treatment while the experimental group had additional montelukast .After 3‐week treat‐ment ,the changes of IL‐6 and IL‐12 before and after treatment were compared for two groups .Also clinical efficacy ,rash resolving time ,abdominal pain and joint swelling resolving time were analyzed .[Results] After treatment ,the serum levels of IL‐6 and IL‐12 levels declined markedly in both groups .However there was a larger decline in experimental group and the inter‐group differences were statistically significant (P<0 .05) . The symptoms improved in both groups .The overall efficacy of experimental group was significantly higher than that of control group (96 .0% vs 76 .0% ,P <0 .05) .And the resolving times of rash ,abdominal pain and joint swelling were shorter in experimental group than those in control group ( P<0 .05) .And no adverse reactions occurred during treatment in neither group .[Conclusion] A combination of conventional treatment and montelukast is both safe and efficacious for HSP children .And improvements of overall efficacy and clini‐cal symptoms may be mediated by a down‐regulation of IL‐6 and IL‐12 .